TWST · Twist Bioscience Corporation · Stock research

Current Thesis

The question the prior note left open — whether AI-drug-discovery orders would show up in the total revenue line or stay a mix story — got answered on 2026-08-03. Q3 FY26 revenue was $118.4M, +23% YoY, against company guidance of $114–115M and a $114.49M consensus. DNA Synthesis and Protein Solutions revenue grew 39% YoY to $56.6M on roughly 369,000 genes shipped; NGS grew 12% to $61.8M. Consolidated growth moved from the ~19% that Evercore ISI called uninflected on 2026-07-06 to 23%. Management raised FY26 revenue guidance to $456–457M from $442–447M, guided Q4 to $123–124M against $117.5M consensus, reaffirmed adjusted-EBITDA breakeven for fiscal Q4, and said it expects at least triple-digit AI order growth in both FY26 and FY27.

What an investor buys here is no longer the possibility of an inflection — that is on the tape. It is the extrapolation: that a business whose adjusted-EBITDA loss narrowed to $11.3M in Q3 crosses into cash generation while AI-designed-protein customers keep re-ordering, and that the ~$1B-by-FY2031 frame set at the 2026-05-21 Investor Day gets pulled forward. The complication is that price got there first. The 2026-08-14 close of $118.57 sits above the freshly raised $115 target cluster and above the $105.3 eleven-analyst average, RSI(14) is 72.8, and the three-month return is +141.1%.

Bullish and bearish views on Twist Bioscience Corporation

The model's bull view on Twist Bioscience Corporation (TWST), in brief: Beat-and-raise on 2026-08-03 with the growth rate accelerating, not just the absolute number: revenue $118.376M vs $114.490M consensus, 14th consecutive quarter of sequential growth, gross margin 52.8%. The bear view: Price is through the entire published target cluster. Both cases follow in full.

Bull Case

• Beat-and-raise on 2026-08-03 with the growth rate accelerating, not just the absolute number: revenue $118.376M vs $114.490M consensus, 14th consecutive quarter of sequential growth, gross margin 52.8%.
• The AI-adjacent segment carried it. DNA Synthesis and Protein Solutions +39% YoY to $56.6M. That is the line the AI-drug-discovery thesis lives in, and it grew nearly double the consolidated rate.
• Guidance raised twice inside one fiscal year: FY26 to $456–457M (from $442–447M on 2026-05-04) versus $446.103M consensus; Q4 FY26 $123.000–124.000M versus $117.546M consensus.
• Path to cash breakeven is narrowing on schedule. Adjusted-EBITDA loss of $11.3M in Q3 with breakeven reaffirmed for fiscal Q4, the same target set at the 2026-05-21 Investor Day.
• The $300.0M raise was absorbed without breaking structure. The deal priced 3,125,000 shares at $96.00 on 2026-08-04 (upsized from the $250M announced that morning), closing expected 2026-08-06 — and the stock subsequently printed a $125.29 52-week high. Supply arriving into a bid, rather than a bid disappearing into supply.
• Sell-side moved up behind the print: Baird $113 → $115 (2026-08-04), Piper Sandler to $115 (2026-08-05), TD Cowen to $115.

Bear Case

• Price is through the entire published target cluster. $118.57 on 2026-08-14 versus a $115 high-water target from the three firms that raised post-print and a $105.3 average across 11 analysts. There is no analyst upside left to quote as a reason to buy; the next leg requires new targets, not existing ones.
• The bottom line still missed. Q3 EPS of -$0.56 versus -$0.50 consensus. Adjusted-EBITDA breakeven is not GAAP profit, and FY25 closed with a -$77.67M net loss.
• Equity was issued into strength and insiders sold into the high. $300.0M of stock priced at $96.00 on 2026-08-04; on 2026-08-10 CEO Emily Leproust exercised 113,318 options at $26.66 and sold the same 113,318 shares at a weighted average $125.1615 (range $125.00–$125.51), leaving 818,938 shares held (Form 4 filed 2026-08-12). The sale ran under a 10b5-1 plan adopted 2025-05-27, so it is scheduled rather than discretionary — but the execution price landed within $0.13 of the 52-week high.
• Dilution is real: 3,125,000 new shares against a float previously cited at 62.27M, following the mixed-shelf registration filed 2026-06-18.
• Nothing scheduled resolves anything for roughly three months. Fiscal Q4 ends 2026-09-30 and results have historically landed in mid-November. A 141% three-month move now has to hold on flow alone.

Setup & Price Structure

The 2026-08-14 close of $118.57 is 5.4% under the $125.29 52-week high, with RSI(14) at 72.8 — extended, and holding it. The structure has three reference shelves stacked below: the $105.47 July high, which the post-print gap converted from resistance into the nearest support; the $96.00 offering price, where 3,125,000 shares changed hands in a single block and marks the level institutional buyers of the deal are measured from; and the $93.85 mid-July consolidation zone (2026-07-17 close).

Crowding observables, stated without a verdict: price above every published price target; RSI(14) 72.8 with the stock inside 6% of its high; a $300.0M primary issuance completed eleven days before the reference close; a 113,318-share insider disposition executed at $125.16 on 2026-08-10; and beta previously cited at 2.11, which has produced double-digit single-session moves in both directions through this advance. New sell-side money is not arriving as initiations — the post-print activity was existing bulls marking targets up to a level price has already passed.

The narrative is maturing. The narrative is well known and still working — the 2026-08-03 print validated it with hard numbers — but the flow signature has moderated from the June–July burst of fresh initiations (Piper 2026-06-11, Canaccord 2026-06-15, Barclays 2026-06-24, Guggenheim 2026-06-29) to target maintenance behind price. It is not saturated while the stock can absorb a $300.0M raise and make a new high six days later; that changes if the next distribution event is met with lower highs.

Catalyst Calendar (next 30 days)

• 2026-08-15 to 2026-09-14 — no scheduled company event identified. Announcements reviewed through 2026-08-14 show no September investor-conference participation confirmed. The window is a catalyst vacuum; price action in it is positioning, not news.
• 2026-09-30 (fiscal Q4 FY26 ends). The quarter in which management has reaffirmed adjusted-EBITDA breakeven. The result is not reported on this date, but the measurement period closes.

Elapsed catalysts

• Rolling — Form 4 filings under the 10b5-1 plan adopted 2025-05-27. After the 2026-08-10 disposition, 153,221 options remain outstanding to the CEO at strikes of $5.95–$67.85. Additional scheduled sales in the $115–125 zone would extend the pattern. (passed 16d ago)
• ~2026-11 (est.) — Q4 and full-year FY26 results plus initial FY27 guidance. The first quantified test of the "at least triple-digit AI order growth in FY27" claim made on the 2026-08-03 call. (passed 23d ago)

What Would Change Our Mind

The post-print breakout shelf is what has to hold. Price gapped through the $105.47 July high on the 2026-08-03 beat and has not revisited it; losing that shelf would mean the entire Q3 re-rating was given back with the fundamental news unchanged, which is the signature of a crowd exiting rather than a thesis failing — and either way the leg is over. A weekly close below $105 marks that.

Second, the fundamentals themselves. Fiscal Q4 revenue printing below the $123.000–124.000M guide, or adjusted EBITDA missing the breakeven that has been reaffirmed twice (2026-05-21 Investor Day, 2026-08-03 call), would break the sequence of raised guidance that carried the stock from June to August. A DNA Synthesis and Protein Solutions growth rate decelerating from +39% back toward the consolidated rate would remove the specific line that makes this an AI story rather than a tools story.

Third, the crowding side. Another primary offering inside 90 days of the 2026-08-04 deal, or continued insider disposition met with a series of lower highs, would move the label from maturing to saturated. Conversely, a fresh initiation above $125 or a target cluster re-set through the current price would argue the flow leg has more to run.

Correlation Notes

Twist sells consumables, not compute, so the AI linkage is second-order: revenue arrives when AI protein-design and antibody-discovery customers convert model output into wet-lab orders. That makes the demand curve a function of biotech R&D budgets — XBI drawdowns, venture funding for AI-native drug-discovery startups, and US academic/NIH funding headlines are the upstream variables, and none of them are visible in a semiconductor tape.

Within life-science tools, the company's growth profile has decoupled from the sequencing-instrument complex: consumables ordered per experiment behave differently from capital equipment cycles, and the 2026 move has been driven by an AI-demand narrative the instrument names do not share. That decoupling works in both directions — a broad tools-sector de-rate would not spare a 2.11-beta name at 72.8 RSI, and a sympathy bid off an AI-drug-discovery peer's results can move it without any Twist-specific news. Inference, not a measured correlation: the co-movement to watch is with AI-protein-design and computational-biology equities rather than with sequencing hardware.